Federated Hermes Inc. Acquires 108,979 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Key Points

• Federated Hermes Inc. has significantly increased its holdings in Y-mAbs Therapeutics by 245% in the first quarter, owning 153,453 shares valued at approximately $680,000.
• Y-mAbs Therapeutics' stock has seen fluctuations, with a current price of $8.51, reflecting a 52-week range of $3.55 to $16.11.
• Analysts currently have a consensus rating of "Hold" for Y-mAbs Therapeutics, with a target price of $8.60, following recent downgrades from some research firms.

Federated Hermes Inc. raised its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 245.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 153,453 shares of the company's stock after buying an additional 108,979 shares during the period. Federated Hermes Inc. owned about 0.34% of Y-mAbs Therapeutics worth $680,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $46,000. Corton Capital Inc. bought a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $55,000. ProShare Advisors LLC bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $99,000. Exchange Traded Concepts LLC boosted its holdings in shares of Y-mAbs Therapeutics by 107.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock worth $119,000 after buying an additional 13,890 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after buying an additional 6,131 shares during the period. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Trading Down 0.1%

Shares of YMAB traded down $0.01 during midday trading on Tuesday, reaching $8.52. The stock had a trading volume of 264,111 shares, compared to its average volume of 477,126. The company's 50-day moving average is $5.02 and its 200 day moving average is $4.95. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.55 and a 12-month high of $16.11. The company has a market capitalization of $385.56 million, a price-to-earnings ratio of -17.03 and a beta of 0.57.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.20. The company had revenue of $19.52 million during the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.34% and a negative net margin of 26.03%. Research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

YMAB has been the topic of a number of research reports. Wedbush downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and set a $8.60 price target on the stock. in a research note on Tuesday, August 5th. Brookline Capital Management downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Canaccord Genuity Group downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and cut their price target for the stock from $26.00 to $8.60 in a research note on Tuesday, August 5th. Jones Trading downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald set a $8.60 price target on Y-mAbs Therapeutics and gave the company a "neutral" rating in a research report on Tuesday, August 5th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $11.16.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.